Wolfgang P Fendler1, Hanna Lechner2, Andrei Todica2, Karolin J Paprottka3, Philipp M Paprottka3, Tobias F Jakobs4, Marlies Michl5, Peter Bartenstein6, Sebastian Lehner2, Alexander R Haug7. 1. Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany wolfgang.fendler@med.uni-muenchen.de. 2. Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany. 3. Department of Clinical Radiology, Ludwig-Maximilians-University of Munich, Munich, Germany. 4. Department of Diagnostic and Interventional Radiology, Hospital Barmherzige Brueder, Munich, Germany. 5. Department of Hematology and Oncology, Ludwig-Maximilians-University of Munich, Munich, Germany. 6. Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany Comprehensive Cancer Center Munich (CCCM), Ludwig-Maximilians-University of Munich, Munich, Germany; and. 7. Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Abstract
UNLABELLED: The present study evaluated safety, efficacy, and prognostic factors for (90)Y-yttrium microsphere radioembolization of unresectable liver metastases from breast cancer. METHODS: Eighty-one patients were treated with radioembolization. Acute toxicity was monitored through daily physical examination and serum tests until 3 d after radioembolization; late toxicity was evaluated until 12 wk after radioembolization. Overall survival and response according to (18)F-FDG PET (>30% decrease of tracer uptake) and CA15-3 serum level (any decline) were recorded. Pretherapeutic characteristics, including pretreatment history, liver function tests, and PET/CT parameters, were assessed by univariate and subsequent multivariate Cox regression for predicting patient survival. RESULTS: A toxicity grade of 3 or more based on clinical symptoms, bilirubin, ulcer, pancreatitis, ascites, or radioembolization-induced liver disease occurred in 10% or less of patients. Two patients eventually died from radioembolization-induced liver disease. Sequential lobar treatment and absence of prior angiosuppressive therapy were both associated with a lower rate of serious adverse events. On the basis of PET/CA15-3 criteria, 52/61% of patients responded to treatment. Median overall survival after radioembolization was 35 wk (interquartile range, 41 wk). Pretherapeutic tumor burden of the liver greater than 50% or more (P< 0.001; hazard ratio, 5.67; 95% confidence interval, 2.41-13.34) and a transaminase toxicity grade of 2 or more (P= 0.009; hazard ratio, 2.15; 95% confidence interval, 1.21-3.80) independently predicted short survival. CONCLUSION: Radioembolization for breast cancer liver metastases shows encouraging local response rates with low incidence of serious adverse events, especially in those patients with sequential lobar treatment or without prior angiosuppressive therapy. High hepatic tumor burden and liver transaminase levels at baseline indicate poor outcome.
UNLABELLED: The present study evaluated safety, efficacy, and prognostic factors for (90)Y-yttrium microsphere radioembolization of unresectable liver metastases from breast cancer. METHODS: Eighty-one patients were treated with radioembolization. Acute toxicity was monitored through daily physical examination and serum tests until 3 d after radioembolization; late toxicity was evaluated until 12 wk after radioembolization. Overall survival and response according to (18)F-FDG PET (>30% decrease of tracer uptake) and CA15-3 serum level (any decline) were recorded. Pretherapeutic characteristics, including pretreatment history, liver function tests, and PET/CT parameters, were assessed by univariate and subsequent multivariate Cox regression for predicting patient survival. RESULTS: A toxicity grade of 3 or more based on clinical symptoms, bilirubin, ulcer, pancreatitis, ascites, or radioembolization-induced liver disease occurred in 10% or less of patients. Two patients eventually died from radioembolization-induced liver disease. Sequential lobar treatment and absence of prior angiosuppressive therapy were both associated with a lower rate of serious adverse events. On the basis of PET/CA15-3 criteria, 52/61% of patients responded to treatment. Median overall survival after radioembolization was 35 wk (interquartile range, 41 wk). Pretherapeutic tumor burden of the liver greater than 50% or more (P< 0.001; hazard ratio, 5.67; 95% confidence interval, 2.41-13.34) and a transaminase toxicity grade of 2 or more (P= 0.009; hazard ratio, 2.15; 95% confidence interval, 1.21-3.80) independently predicted short survival. CONCLUSION: Radioembolization for breast cancer liver metastases shows encouraging local response rates with low incidence of serious adverse events, especially in those patients with sequential lobar treatment or without prior angiosuppressive therapy. High hepatic tumor burden and liver transaminase levels at baseline indicate poor outcome.
Authors: Samdeep K Mouli; Ramona Gupta; Neil Sheth; Andrew C Gordon; Robert J Lewandowski Journal: Semin Intervent Radiol Date: 2018-04-05 Impact factor: 1.513
Authors: K J Paprottka; F Schoeppe; M Ingrisch; J Rübenthaler; N N Sommer; E De Toni; H Ilhan; M Zacherl; A Todica; P M Paprottka Journal: Eur J Nucl Med Mol Imaging Date: 2017-02-14 Impact factor: 9.236
Authors: B M Aarts; F M Gómez Muñoz; H Wildiers; V O Dezentjé; T R Baetens; W Schats; M Lopez-Yurda; R C Dresen; B J de Wit-van der Veen; C M Deroose; G Maleux; R G H Beets-Tan; E G Klompenhouwer Journal: Cardiovasc Intervent Radiol Date: 2021-07-28 Impact factor: 2.740
Authors: Andrew Kennedy; Daniel B Brown; Jonas Feilchenfeldt; John Marshall; Harpreet Wasan; Marwan Fakih; Peter Gibbs; Alexander Knuth; Bruno Sangro; Michael C Soulen; Gianfranco Pittari; Ricky A Sharma Journal: J Gastrointest Oncol Date: 2017-12
Authors: Daniel Brown; Henry Krebs; Jayson Brower; Ryan O'Hara; Eric Wang; Kirubahara Vaheesan; Liping Du; Lea Matsuoka; Donna D'Souza; Daniel Y Sze; Jafar Golzarian; Ripal Gandhi; Andrew Kennedy Journal: J Gastrointest Oncol Date: 2021-04
Authors: Fourat Ridouani; Mohamed M Soliman; Ryan W England; Meier Hsu; Chaya S Moskowitz; Raphael Doustaly; Constantinos T Sofocleous; F Edward Boas; Hooman Yarmohammadi; Amy R Deipolyi Journal: Eur J Radiol Date: 2021-01-12 Impact factor: 3.528